Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 16, Issue 3, Pages 537-558Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2011.604312
Keywords
ALS; disease-modifying drugs; frontotemporal dementia; riluzole
Categories
Funding
- Avanir Pharmaceuticals
- Teva Neuroscience Inc.
- NeuralStem
- Knopp Biosciences
- Cytokinetics
- Sanofi-Aventis
- Biogen Idec
Ask authors/readers for more resources
Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that results in increasing disability and that is uniformly fatal. Since its approval in the 1990s, riluzole remains the sole treatment for ALS offering modest survival benefit. While significant advances have been made in the symptomatic management of the disease, more effective drug therapy targeting disease progression is sorely needed. Areas covered: Advances in the understanding of pathogenic mechanisms involved in disease development and progression have provided multiple avenues for developing effective treatment strategies. This review highlights recent discoveries relating to these diverse mechanisms and their implications for the development of drug therapy. Previous human clinical trials that have targeted these pathways are mentioned and ongoing drug trials are discussed. Expert opinion: The search for effective drug therapy faces important challenges in the areas of basic science and animal research, translation of these results into human clinical trials, inherent bias in human studies and issues related to delays in clinical diagnosis. How these issues may be addressed and why ALS research constitutes fertile grounds for drug development not only for this devastating disease, but also for other more prevalent neurodegenerative diseases, is discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available